Liposomal drug delivery systems for the treatment of leishmaniasis

Imagem de Miniatura
Arquivos
art_TUON_Liposomal_drug_delivery_systems_for_the_treatment_of_2022.PDF (979.59 KB)
Citações na Scopus
10
Tipo de produção
article
Data de publicação
2022
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER
Autores
TUON, Felipe Francisco
DANTAS, Leticia Ramos
RIBEIRO, Victoria Stadler Tasca
Citação
PARASITOLOGY RESEARCH, v.121, n.11, p.3073-3082, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Human leishmaniasis is a vector-borne, neglected infectious disease that is widely distributed in America, Africa, Europe, and Asia. Current therapy is based on old and toxic drugs, including antimonials, aminoglycosides, and amphotericin. As a neglected disease, investment in the development of new therapeutic molecules is scarce. Considering these aspects, the optimization of treatment through novel delivery systems for current therapeutic agents is an attractive alternative. The encapsulation into liposomes of drugs used in treating leishmaniasis increases the concentration of these molecules in macrophages, which may not only increase the chance of cure but also expand their therapeutic spectrum to include resistant Leishmania, as well as reducing toxicity since the drug is less exposed to healthy cells. The classical example is the liposomal formulation of amphotericin B, a well-established therapeutic option that uses liposomes to decrease the progression of renal failure in patients. However, loading other leishmanicidal drugs into liposomes, such as pentavalent antimonials, presents an opportunity for innovative and cheaper therapeutic options for the treatment of human leishmaniasis. This review aims to discuss liposomes as a drug delivery system for leishmanicidal drugs.
Palavras-chave
Leishmaniasis, Liposomes, Drug delivery system, Parasites
URI
https://observatorio.fm.usp.br/handle/OPI/50536
Referências
  1. Altamura F, 2022, DRUG DEVELOP RES, V83, P225, DOI 10.1002/ddr.21664
  2. Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671
  3. Amato VS, 2009, J EUR ACAD DERMATOL, V23, P1026, DOI 10.1111/j.1468-3083.2009.03238.x
  4. Amato VS, 2011, AM J TROP MED HYG, V85, P818, DOI 10.4269/ajtmh.2011.11-0287
  5. Amato VS, 2008, ACTA TROP, V105, P1, DOI 10.1016/j.actatropica.2007.08.003
  6. Amato VS, 2007, AM J TROP MED HYG, V77, P266, DOI 10.4269/ajtmh.2007.77.266
  7. Amato VS, 2007, CLIN INFECT DIS, V44, P311, DOI 10.1086/510494
  8. Amato VS, 2009, INT J DERMATOL, V48, P1091, DOI 10.1111/j.1365-4632.2009.04099.x
  9. Amer Eglal I, 2016, J Parasit Dis, V40, P475, DOI 10.1007/s12639-014-0529-0
  10. Azevedo EG, 2014, EXPERT OPIN DRUG DEL, V11, P1551, DOI 10.1517/17425247.2014.932347
  11. Bacha HA, 2011, T ROY SOC TROP MED H, V105, P173, DOI 10.1016/j.trstmh.2010.11.010
  12. Tuon FF, 2009, INT J DERMATOL, V48, P201, DOI 10.1111/j.1365-4632.2009.03982.x
  13. Silva JRV, 2020, EXP PARASITOL, V217, DOI 10.1016/j.exppara.2020.107934
  14. Valladares JE, 1997, AM J TROP MED HYG, V57, P403, DOI 10.4269/ajtmh.1997.57.403
  15. Varma DM, 2021, ACS BIOMATER SCI ENG, V7, P1725, DOI 10.1021/acsbiomaterials.0c01132
  16. VENNERSTROM JL, 1990, ANTIMICROB AGENTS CH, V34, P918, DOI 10.1128/AAC.34.5.918
  17. Tavares GDV, 2018, BASIC CLIN PHARMACOL, V123, P236, DOI 10.1111/bcpt.12990
  18. Want MY, 2017, INT J NANOMED, V12, P2189, DOI 10.2147/IJN.S106548
  19. Wolf B, 1998, DRUG DEV IND PHARM, V24, P1007, DOI 10.3109/03639049809089944
  20. Wyllie S, 2004, J BIOL CHEM, V279, P39925, DOI 10.1074/jbc.M405635200
  21. YANG DM, 1993, PARASITOLOGY, V106, P7, DOI 10.1017/S0031182000074758
  22. Yesilova Y, 2016, J DERMATOL TREAT, V27, P83, DOI 10.3109/09546634.2015.1054778
  23. Zhang RY, 2010, PARASITOL RES, V107, P475, DOI 10.1007/s00436-010-1906-y
  24. Basu MK, 2004, CURR MOL MED, V4, P681, DOI 10.2174/1566524043360186
  25. Belo VS, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002982
  26. BERMAN JD, 1985, ANTIMICROB AGENTS CH, V27, P916, DOI 10.1128/AAC.27.6.916
  27. Burza S, 2018, LANCET, V392, P951, DOI 10.1016/S0140-6736(18)31204-2
  28. Calvo A, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12090858
  29. Camargo RA, 2010, AM J TROP MED HYG, V83, P515, DOI 10.4269/ajtmh.2010.10-0081
  30. Cury TAC, 2015, J MICROENCAPSUL, V32, P467, DOI 10.3109/02652048.2015.1046518
  31. Carneiro G, 2010, J LIPOSOME RES, V20, P16, DOI 10.3109/08982100903015025
  32. Carvalheiro M, 2015, EUR J PHARM BIOPHARM, V93, P346, DOI 10.1016/j.ejpb.2015.04.018
  33. Cauchetier E, 2000, INT J PARASITOL, V30, P777, DOI 10.1016/S0020-7519(00)00053-9
  34. CHAN MMY, 1990, SCIENCE, V249, P924, DOI 10.1126/science.2392684
  35. Chan-Bacab MJ, 2009, J ANTIMICROB CHEMOTH, V63, P1292, DOI 10.1093/jac/dkp117
  36. Cogo J, 2018, BIOORGAN MED CHEM, V26, P4065, DOI 10.1016/j.bmc.2018.06.033
  37. Craft N, 2014, CLIN VACCINE IMMUNOL, V21, P1314, DOI 10.1128/CVI.00338-14
  38. Croft SL, 2006, CLIN MICROBIOL REV, V19, P111, DOI 10.1128/CMR.19.1.111-126.2006
  39. CROFT SL, 1992, J ANTIMICROB CHEMOTH, V30, P827, DOI 10.1093/jac/30.6.827
  40. Dar MJ, 2020, EUR J PHARM SCI, V145, DOI 10.1016/j.ejps.2020.105256
  41. Dar MJ, 2018, DRUG DELIV, V25, P1595, DOI 10.1080/10717544.2018.1494222
  42. de Almeida L, 2017, J BIOMED NANOTECHNOL, V13, P117, DOI 10.1166/jbn.2017.2349
  43. de Barros NB, 2016, INT IMMUNOPHARMACOL, V36, P225, DOI 10.1016/j.intimp.2016.04.025
  44. de Camargo RA, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003001
  45. Emami T, 2018, ARTIF CELL NANOMED B, V46, P324, DOI 10.1080/21691401.2018.1457042
  46. Bafghi AF, 2021, PREP BIOCHEM BIOTECH, V51, P990, DOI 10.1080/10826068.2021.1885045
  47. Ferreira FM, 2014, PARASITOL RES, V113, P533, DOI 10.1007/s00436-013-3685-8
  48. Ferreira LS, 2004, DRUG DEV IND PHARM, V30, P289, DOI 10.1081/DDC-120030423
  49. Fuentes-Nava G, 2021, REV SOC BRAS MED TRO, V54, DOI 10.1590/0037-8682-0305-2020
  50. Gardner DM, 2010, PHOTOCHEM PHOTOBIOL, V86, P645, DOI 10.1111/j.1751-1097.2010.00705.x
  51. Gebreyohannes EA, 2018, INFECT DIS POVERTY, V7, DOI 10.1186/s40249-018-0491-7
  52. Gharbi M, 2020, TRANSBOUND EMERG DIS, V67, P8, DOI 10.1111/tbed.13312
  53. Grover R, 1997, Rev Environ Contam Toxicol, V153, P1
  54. Hussain Z, 2019, DRUG DELIV TRANSL RE, V9, P721, DOI 10.1007/s13346-019-00631-4
  55. Karimkhani C, 2017, LANCET INFECT DIS, V17, P264, DOI 10.1016/S1473-3099(16)30217-1
  56. Karimkhani C, 2016, LANCET INFECT DIS, V16, P584, DOI 10.1016/S1473-3099(16)00003-7
  57. Khalil EAG, 2006, SAUDI MED J, V27, P90
  58. Lala S, 2004, J DRUG TARGET, V12, P165, DOI 10.1080/10611860410001712696
  59. Lasic DD, 1998, TRENDS BIOTECHNOL, V16, P307, DOI 10.1016/S0167-7799(98)01220-7
  60. Lopes RM, 2016, NANOMEDICINE-UK, V11, P153, DOI 10.2217/nnm.15.190
  61. Mantyla A, 2004, J MED CHEM, V47, P188, DOI 10.1021/jm030868a
  62. Marti-Marti I, 2021, ENFERM INFEC MICR CL, V39, P108, DOI 10.1016/j.eimc.2020.04.005
  63. Matlashewski G, 2011, LANCET INFECT DIS, V11, P322, DOI 10.1016/S1473-3099(10)70320-0
  64. MCHARDY N, 1985, RES VET SCI, V39, P29, DOI 10.1016/S0034-5288(18)31765-X
  65. Medda S, 1999, J ANTIMICROB CHEMOTH, V44, P791, DOI 10.1093/jac/44.6.791
  66. Medkour H, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008947
  67. Mesquita JT, 2013, ACTA TROP, V128, P666, DOI 10.1016/j.actatropica.2013.09.018
  68. Minodier P, 2008, PEDIATR INFECT DIS J, V27, P80, DOI 10.1097/INF.0b013e3181506683
  69. Monteiro LM, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/9781603
  70. Moosavian SA, 2019, EXP PARASITOL, V200, P30, DOI 10.1016/j.exppara.2019.03.004
  71. NEAL RA, 1988, ANN TROP MED PARASIT, V82, P453, DOI 10.1080/00034983.1988.11812275
  72. Oliveira MC, 2005, REV SOC BRAS MED TRO, V38, P258, DOI 10.1590/S0037-86822005000300011
  73. Owais M., 2005, Current Drug Delivery, V2, P311, DOI 10.2174/156720105774370177
  74. Pal S, 2004, ANTIMICROB AGENTS CH, V48, P3591, DOI 10.1128/AAC.48.9.3591-3593.2004
  75. Passos SR, 2014, INT J ANTIMICROB AG, V44, P463, DOI 10.1016/j.ijantimicag.2014.07.011
  76. Peine KJ, 2014, J ANTIMICROB CHEMOTH, V69, P168, DOI 10.1093/jac/dkt320
  77. Pinto EG, 2020, CHEM-BIOL INTERACT, V332, DOI 10.1016/j.cbi.2020.109296
  78. Pokharel P, 2021, J TROP MED-US, V2021, DOI 10.1155/2021/8629039
  79. Proulx ME, 2001, ANTIMICROB AGENTS CH, V45, P2623, DOI 10.1128/AAC.45.9.2623-2627.2001
  80. Raay B, 1999, INDIAN J BIOCHEM BIO, V36, P248
  81. Rajabi O, 2016, DERMATOL THER, V29, P358, DOI 10.1111/dth.12357
  82. Ramos GS, 2021, BIOMED PHARMACOTHER, V134, DOI 10.1016/j.biopha.2020.111120
  83. Reimao JQ, 2012, EXP PARASITOL, V130, P195, DOI 10.1016/j.exppara.2012.01.010
  84. Reimao JQ, 2010, PARASITOL RES, V106, P1465, DOI 10.1007/s00436-010-1826-x
  85. Reis PG, 2013, J AOAC INT, V96, P771, DOI 10.5740/jaoacint.10-263
  86. Rocio C, 2014, T ROY SOC TROP MED H, V108, P176, DOI 10.1093/trstmh/tru011
  87. Romanelli MM, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00353
  88. Roychoudhury J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017376
  89. Sanna V, 2014, INT J NANOMED, V9, P467, DOI 10.2147/IJN.S36654
  90. Santos CCP, 2020, ANTIMICROB AGENTS CH, V64
  91. Santos J, 2000, An Med Interna, V17, P562
  92. Schettini DA, 2006, INT J PHARMACEUT, V315, P140, DOI 10.1016/j.ijpharm.2006.01.048
  93. Schwendener RA, 2007, ADV EXP MED BIOL, V620, P117
  94. Sen R, 2010, INT J ANTIMICROB AG, V36, P43, DOI 10.1016/j.ijantimicag.2010.03.008
  95. Smith L, 2018, MOL PHARMACEUT, V15, P2570, DOI 10.1021/acs.molpharmaceut.8b00097
  96. Reis LES, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.00962-17
  97. Sundar S, 2010, J GLOB INFECT DIS, V2, P159, DOI 10.4103/0974-777X.62886
  98. Tavares GSV, 2019, PARASITOL INT, V68, P63, DOI 10.1016/j.parint.2018.10.005
  99. Taylor VM, 2011, ANTIMICROB AGENTS CH, V55, P4755, DOI 10.1128/AAC.00671-11
  100. Teixeira AC, 2008, REV INST MED TROP SP, V50, P157, DOI 10.1590/S0036-46652008000300005
  101. Tempone AG, 2010, INT J ANTIMICROB AG, V36, P159, DOI 10.1016/j.ijantimicag.2010.04.006
  102. Borborema SET, 2018, BIOMED PHARMACOTHER, V103, P1609, DOI 10.1016/j.biopha.2018.05.004
  103. Borborema SET, 2011, INT J ANTIMICROB AG, V38, P341, DOI 10.1016/j.ijantimicag.2011.05.012
  104. Tuon FF, 2008, REV INST MED TROP SP, V50, P313, DOI 10.1590/S0036-46652008000500013
  105. Tuon FF, 2008, INT J DERMATOL, V47, P109, DOI 10.1111/j.1365-4632.2008.03417.x
  106. Tuon FF, 2007, CLIN INFECT DIS, V44, P1525, DOI 10.1086/517848

Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - LIM/46